Why the study?
Does cardiac resynchronisation therapy improve morbidity and mortality in selected heart failure patients?
Does cardiac resynchronisation therapy improve morbidity and mortality in selected heart failure patients?
Answers are grounded in this paper and cite their sources.
This review summarizes the established benefits of cardiac resynchronisation therapy on morbidity and mortality in specific heart failure populations and highlights areas needing further research.
The number of people in Europe living with symptomatic heart failure is increasing. Since its advent in the 1990s, cardiac resynchronisation therapy (CRT) has proven beneficial in terms of morbidity and mortality in selected heart failure (HF) patient populations, when combined with optimal pharmacological therapy. We review the evidence for CRT and the populations of HF patients it is currently shown to benefit, and those in which more research needs to be performed.
No takes yet. Share an insight, caveat, or question.
Dewhurst et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: